We wanted to ensure that the cell response observed could be appropriately

EZH2 through the use of a low-homology vSET structure that also binds H3K27. This suggests that the design of such histone-modifying enzymes may not need an exact experimental structure, but rather a structure of a protein that binds the same substrate. Perhaps the specific binding interactions necessary for design are conserved across enzymes that modify identical sites. If so, this would allow structure based design methods to target a wider range of enzymatic targets than previously thought. It is also important to retrospectively analyze the biological constraints used in the study to see if there are trends that may be important for future designs. There were four sets of biological constraints used in this study: fixed P30 and G33 with sequence rearrangement only, fixed P30 and G33 with up to five rearrangements, up to five mutations, and fixed P30 and G33 with an upper bound of two on the number of each amino acid type. All sets maintained the native charge of +3. From the endpoint assay results presented in Cantharidin Figure 3.A, SQ037, SQ040, and SQ043 stood out qualitatively in comparison to control. The quantitative inhibitory assays and IC50 results confirmed that these three peptides were among the best designed inhibitors. All three of the peptides were derived from Run 4 of the Sequence Selection stage. Comparing the sequences from Run 4 to the other runs, a distinct charge feature of the sequences can be identified. While all the runs were forced to maintain the native charge of +3 on the designed peptides, Run 4 had loose mutational constraints that allowed for the addition of pairs of negatively and positively charged amino acids. This resulted in a MCE Chemical α-Asarone higher charge content in the sequences, especially in positions 22�C25, without a change in overall charge. This charge feature may be important for EZH2 inhibition and could be used to guide future inhibitor design. The designed peptide SQ026 from Run 3 also deserves some analysis as it is the only successful design where P30 and G33 mutations were tolerated and had the second lowest IC50 value after SQ037. Analyzing this sequence in reference to the other unsuccessful peptide designs from Run 3 and the successful designs from Run 4, a consistent mutation of S28N is observed for successful inhibitor design. This could be an important mutation for inhibiti